載入中
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
前收盤價
US$4.87
+US$0.23 · +4.96%
盤前
US$4.92
+US$0.05 · +1.03%
10月12日 上午9:14 ET
盤中時間採用ET。市場資料可能有所延遲。
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
日內區間
目前US$4.87
52週區間
目前US$4.87
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 3.1萬 USD | — | — | — | — |
| 毛利 | −3.1萬 USD | — | — | — | — |
| 研究與開發 | 5379.8萬 USD | 6152.7萬 USD | 5574.3萬 USD | 4381.3萬 USD | 3248.6萬 USD |
| 銷售、一般及管理費用 | 2916.8萬 USD | 1836.7萬 USD | 1468萬 USD | 1217.7萬 USD | 935.7萬 USD |
| 營業費用 | 8296.6萬 USD | 7989.4萬 USD | 7042.3萬 USD | 5599萬 USD | 4184.3萬 USD |
| 利息收入 | 488萬 USD | 548.2萬 USD | 487萬 USD | 420.8萬 USD | 8萬 USD |
| 利息支出 | — | — | — | — | 180.7萬 USD |
| 折舊和攤銷 | 3.1萬 USD | 3.1萬 USD | 3.6萬 USD | 3萬 USD | 1.3萬 USD |
| 營業利益 | −8296.6萬 USD | −7989.4萬 USD | −7042.3萬 USD | −5599萬 USD | −4184.3萬 USD |
| 淨利 | −7758.6萬 USD | −7441.2萬 USD | −6845.9萬 USD | −5178.7萬 USD | −4106萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$9.17
上漲空間 88.30%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2020年10月13日 | 1:50 | — | — |
股票分割 | 2014年5月1日 | 1:6 | — | — |
已生效 2020年10月13日
1:50
已生效 2014年5月1日
1:6
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1287.24萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM979.5萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF477.29萬0.00%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS221.42萬0.01%338.69億 USD0.31%US$78.35+0.32%
Vanguard Russell 2000 ETFVTWO211.14萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA189.96萬0.01%218.24億 USD0.03%US$32.79+0.40%
Fidelity Enhanced Small Cap ETFFESM178.81萬0.03%64.1億 USD0.28%US$45.46+0.46%
Janus Henderson Small Cap Growth Alpha ETFJSML124.06萬0.34%3.61億 USD0.30%US$87.477+1.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
